Profile data is unavailable for this security.
About the company
Akari Therapeutics, Plc is a biotechnology company developing precision bifunctional antibody drug conjugates (ADC) for the treatment of cancer. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. It is pursuing research on two additional novel payloads, such as PH5 and PH6. It also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.
- Revenue in USD (TTM)0.00
- Net income in USD-15.77m
- Incorporated2004
- Employees8.00
- LocationAkari Therapeutics PLC401 EAST JACKSON STREET, SUITE 3300TAMPA 33602United StatesUSA
- Phone+1 (929) 274-7510
- Fax+1 (646) 843-9352
- Websitehttps://www.akaritx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nutraproducts Inc | 0.00 | -821.94k | 7.85m | 0.00 | -- | 1.31 | -- | -- | -1.31 | -1.31 | 0.00 | 0.2973 | 0.00 | -- | -- | -- | -513.70 | -1,177.23 | -740.45 | -- | -- | -- | -- | -- | -- | -385.17 | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Tian'an Pharmaceutical Co Ltd | 10.65m | 3.14m | 8.00m | -- | 0.0445 | 0.0097 | 2.20 | 0.7511 | 0.2246 | 0.2246 | 0.7611 | 1.03 | -- | -- | -- | -- | -- | -- | -- | -- | 68.54 | -- | 29.51 | -- | 13.36 | 25.66 | 0.00 | -- | 50.51 | -- | 106.71 | -- | -- | -- |
| cbdMD Inc | 19.09m | -3.71m | 8.06m | 42.00 | -- | 0.8588 | -- | 0.4222 | -2.23 | -2.23 | 3.11 | 0.8945 | 1.64 | 2.95 | 15.97 | -- | -20.06 | -48.27 | -41.11 | -54.99 | 60.59 | 63.95 | -12.25 | -85.60 | 1.87 | -- | 0.00 | -- | -1.50 | -14.45 | 43.21 | -- | -32.56 | -- |
| Gelteq Ltd | 117.16k | -4.70m | 8.46m | 7.00 | -- | 0.757 | -- | 72.22 | -0.498 | -0.498 | 0.0124 | 1.04 | 0.0078 | -- | 0.5155 | 16,737.72 | -31.47 | -17.38 | -40.60 | -19.16 | -- | -- | -4,011.74 | -4,507.46 | -- | -3.52 | 0.2106 | -- | -- | -- | -87.40 | -- | -- | -- |
| Nexgel Inc | 11.67m | -2.88m | 8.47m | 19.00 | -- | 1.63 | -- | 0.726 | -0.3796 | -0.3796 | 1.53 | 0.6369 | 1.05 | 3.79 | 13.46 | 613,947.40 | -25.14 | -39.08 | -36.83 | -49.79 | 38.30 | 19.60 | -23.91 | -105.40 | 1.08 | -51.36 | 0.1439 | -- | 112.47 | 64.69 | -3.93 | -- | -- | -- |
| Cuprina Holdings (Cayman) Ltd | 23.79k | -2.22m | 8.59m | 14.00 | -- | 1.43 | -- | 361.22 | -0.1222 | -0.1222 | 0.0013 | 0.2806 | 0.0049 | 13.39 | 0.7976 | 1,699.16 | -44.56 | -- | -131.50 | -- | -69.27 | -- | -9,194.46 | -- | 3.58 | -306.25 | 0.0244 | -- | -52.05 | -- | -39.39 | -- | -- | -- |
| Integrated Biopharma Inc | 52.09m | -206.00k | 9.32m | 153.00 | -- | 0.4717 | 81.79 | 0.179 | -0.007 | -0.007 | 1.67 | 0.6365 | 2.12 | 4.94 | 13.32 | 340,464.10 | -0.8373 | 9.98 | -1.03 | 13.68 | 7.81 | 10.74 | -0.3955 | 4.58 | 2.67 | -- | 0.0069 | -- | 8.02 | 0.5933 | 482.30 | -30.67 | -0.8556 | -- |
| Bon Natural Life Ltd | 18.67m | -1.99m | 9.93m | 96.00 | 18.29 | 0.2274 | -- | 0.5319 | 0.088 | 0.088 | 6.74 | 7.08 | 0.2541 | 6.07 | 1.64 | 194,486.40 | -2.79 | 5.82 | -3.97 | 7.86 | 20.77 | 28.53 | -10.98 | 10.83 | 1.61 | -4.44 | 0.1735 | 0.00 | -21.70 | 0.4899 | -577.58 | -- | 18.20 | -- |
| Biofrontera Inc | 37.17m | -17.57m | 10.44m | 92.00 | -- | -- | -- | 0.2809 | -1.84 | -1.84 | 4.07 | -0.2216 | 2.19 | 2.44 | 9.45 | 403,967.40 | -103.57 | -48.03 | -339.69 | -77.55 | 64.41 | 48.93 | -47.28 | -60.99 | 0.8033 | -47.48 | 2.37 | -- | 9.54 | 7.35 | 11.78 | -- | -35.51 | -- |
| Lotus Pharmaceuticals Inc | 70.79m | 1.72m | 10.74m | 233.00 | 0.0734 | 0.0011 | 2.78 | 0.1518 | 0.0553 | 0.0553 | 2.56 | 3.58 | 0.6321 | 37.27 | 17.85 | 303,836.90 | 1.55 | 22.84 | 1.71 | 26.40 | 35.10 | 41.62 | 2.45 | 19.93 | 0.4428 | 30.80 | 0.0516 | 0.00 | 28.71 | 31.70 | -12.22 | 51.11 | 70.48 | -- |
| Akari Therapeutics PLC (ADR) | 0.00 | -15.77m | 11.45m | 8.00 | -- | -- | -- | -- | -0.600 | -0.600 | 0.00 | -- | 0.00 | -- | -- | 0.00 | -65.57 | -112.46 | -136.47 | -257.78 | -- | -- | -- | -- | -- | -27.77 | 0.0854 | -- | -- | -- | -97.75 | -- | -- | -- |
| Cellectar Biosciences Inc | 0.00 | -18.85m | 12.30m | 11.00 | -- | 1.24 | -- | -- | -10.78 | -10.78 | 0.00 | 2.94 | 0.00 | -- | -- | 0.00 | -72.62 | -104.57 | -141.24 | -133.43 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.23 | -- | 33.54 | -- |
| CV Sciences Inc | 14.37m | -1.48m | 12.70m | 47.00 | -- | 8.25 | -- | 0.8837 | -0.008 | -0.008 | 0.078 | 0.0084 | 1.87 | 1.67 | 34.74 | 305,659.60 | -19.21 | -44.92 | -66.32 | -105.32 | 47.04 | 42.89 | -10.29 | -49.08 | 0.2125 | -2.02 | 0.3829 | -- | -1.87 | -21.80 | -177.18 | -- | -56.43 | -- |
| Hoth Therapeutics Inc | 0.00 | -12.16m | 15.98m | 2.00 | -- | 1.89 | -- | -- | -1.06 | -1.06 | 0.00 | 0.5442 | 0.00 | -- | -- | 0.00 | -138.61 | -129.47 | -154.67 | -144.30 | -- | -- | -- | -- | -- | -493.48 | 0.00 | -- | -- | -- | -4.37 | -- | -- | -- |
| Natural Alternatives International Inc | 135.16m | -12.25m | 17.11m | 293.00 | -- | 0.2552 | -- | 0.1266 | -2.04 | -2.04 | 22.56 | 10.85 | 0.8736 | 4.35 | 7.80 | 461,286.70 | -7.92 | 0.4593 | -9.61 | 0.5479 | 9.06 | 12.75 | -9.06 | 0.4296 | 0.855 | -1.80 | 0.1787 | 0.00 | 14.12 | 1.78 | -88.10 | -- | -4.46 | -- |
Data as of Mar 04 2026. Currency figures normalised to Akari Therapeutics PLC's reporting currency: US Dollar USD
9.52%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Dec 2025 | 2.72m | 5.95% |
| Cresset Asset Management LLCas of 31 Dec 2025 | 822.47k | 1.80% |
| Warberg Asset Management LLCas of 31 Dec 2025 | 308.34k | 0.67% |
| Palo Alto Investors LPas of 31 Dec 2025 | 146.02k | 0.32% |
| Hightower Advisors LLCas of 31 Dec 2025 | 79.24k | 0.17% |
| Jane Street Capital LLCas of 31 Dec 2025 | 71.64k | 0.16% |
| SmartHarvest Portfolios LLCas of 31 Dec 2025 | 69.25k | 0.15% |
| CWA Asset Management Group LLCas of 31 Dec 2025 | 55.00k | 0.12% |
| XTX Markets LLCas of 31 Dec 2025 | 49.02k | 0.11% |
| UBS Securities LLCas of 31 Dec 2025 | 32.86k | 0.07% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
